Mga Batayang Estadistika
| LEI | 549300I2PVFBC9MFAC61 |
| CIK | 1477449 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Teladoc Health, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 30, 2025 |
Exhibit 10.2 ARTICLE I. PURPOSE The purposes of this Teladoc Health, Inc. 2015 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of Teladoc Health, Inc., a Delaware corporation (the “Company”), and its Designated Subsidiaries in acquiring a stock ownership interest in the Company pursuant to a plan which is intended to qu |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TEL |
|
| July 29, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) July 29, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04- |
|
| July 29, 2025 |
Teladoc Health Reports Second Quarter 2025 Results Exhibit 99.1 Teladoc Health Reports Second Quarter 2025 Results NEW YORK, NY, July 29, 2025— Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended June 30, 2025 (“Second Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2024 (“Second Quarter 2024”). Highlig |
|
| July 23, 2025 |
Exhibit 10.1 CREDIT AGREEMENT dated as of July 17, 2025 among TELADOC HEALTH, INC., as Borrower The Lenders Party Hereto JPMORGAN CHASE BANK, N.A., as Administrative Agent, Issuing Bank and Swingline Lender and JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., WELLS FARGO BANK, NATIONAL ASSOCIATION, TRUIST SECURITIES, INC. AND ROYAL BANK OF CANADA as Joint Lead Arrangers and Joint Bookrunners TABLE OF CO |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 17, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04- |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 155 E 44th Street, Floor 17 New York, New York 10017 (Address of Principal |
|
| May 23, 2025 |
First Amendment to Teladoc Health, Inc. 2023 Incentive Award Plan. Exhibit 10.1 FIRST AMENDMENT TO TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN The 2023 Incentive Award Plan (the “Plan”) of Teladoc Health, Inc., a Delaware corporation (the “Company”), is hereby amended, subject to the approval of the Company’s shareholders, effective as of May 22, 2025 (the “Amendment Effective Date”), as follows: 1.Amendment to Section 11.26 of the Plan. Section 11.26 of the P |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 22, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3 |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 1, 2025 |
UNITED STATES DRAFT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES DRAFT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 30, 2025 |
Teladoc Health Reports First Quarter 2025 Results Exhibit 99.1 Teladoc Health Reports First Quarter 2025 Results PURCHASE, NY, April 30, 2025— Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2025 (“First Quarter 2025”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2024 (“First Quarter 2024”). First Q |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) April 30, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04 |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 8, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| February 27, 2025 |
Exhibit 10.45 EXECUTIVE SEVERANCE AGREEMENT This Executive Severance Agreement (“Agreement”) is made effective as of July 14, 2017 (“Effective Date”), by and between Teladoc, Inc. (the “Company”) and Ms. Kelly Bliss, an individual resident in the Commonwealth of Massachusetts (“Executive”). WHEREAS, Executive is a key employee of the Company and the Company and Executive desire to set forth herein |
|
| February 27, 2025 |
Exhibit 10.49 RETENTION BONUS AGREEMENT This Retention Bonus Agreement (this “Agreement”) is made as of April 26, 2024 (the “Effective Date”), between Teladoc Health, Inc. (together with any of its successors or assigns, the “Company”), and Carlos Nueno (the “Employee”). The Company and the Employee are sometimes hereinafter referred to individually as a “Party” and together as “Parties.” WHEREAS, |
|
| February 27, 2025 |
Calculation of Filing Fee Tables S-8 Teladoc Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share Other 1,000,000 $ 11.51 $ 11,510,000.00 0.0001531 $ 1,762.18 Total Offe |
|
| February 27, 2025 |
Second Amendment to Teladoc Health, Inc. 2023 Employment Inducement Award Plan. Exhibit 10.25 SECOND AMENDMENT TO TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN The 2023 Employment Inducement Incentive Award Plan (as amended, the “Plan”) of Teladoc Health, Inc., a Delaware corporation (the “Company”), is hereby amended, effective as of February 27, 2025 (the “Amendment Effective Date”), as follows: 1. Amendment to Section 11.27 of the Plan. Section 11.27 |
|
| February 27, 2025 |
Teladoc Health, Inc. Insider Trading Compliance Policy Exhibit 19.1 Effective February 17, 2023 TELADOC HEALTH, INC. INSIDER TRADING COMPLIANCE POLICY I. SUMMARY Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of Teladoc Health, Inc. (together with its subsidiaries, the “Company”), as well as that of all persons affiliated with the Company. “Insider trading” is a crime, and occurs whe |
|
| February 27, 2025 |
Exhibit 10.48 Execution Version 31 May 2018 ADVANCE MEDICAL HEALTH-CARE MANAGEMENT SERVICES, S.A. (as Company) and Mr Nueno (as Executive Director) SERVICES AGREEMENT Barcelona, on 31 May 2018 THE PARTIES On the one part, ADVANCE MEDICAL HEALTH-CARE MANAGEMENT SERVICES, S.A., a company organized and existing under the laws of Spain, registered with the Commercial Registry of Barcelona with registe |
|
| February 27, 2025 |
Exhibit 10.46 AMENDMENT NO. 1 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 1 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Ms. Kelly Bliss, an individual resident in the Commonwealth of Massachusetts (“Executive”), is made as of April 26, 2024. Recitals A. Teladoc and Executive are parties t |
|
| February 27, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Teladoc Health, Inc. Name Domestic Jurisdiction Advance Medical, Inc. Massachusetts Advanced Medical Healthcare Management Consulting (Shanghai) Co., Ltd. China AM Healthcare Management Consulting Sdn. Bhd. Malaysia Association pour le Déploiement de Parcours de Santé Territoriaux et Phygitaux France Best Doctors Holdings, Inc. Delaware Best Doctors, Inc. Delaware Bett |
|
| February 27, 2025 |
Specimen stock certificate evidencing shares of common stock. COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS. CUSIP 87918A 10 5 FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF $0.001 PAR VALUE EACH OF TELADOC HEALTH, INC. transferable on the books of the Corporation in person or by attorney upon surrender of this certificate duly endorsed or assigned. This certificate and the shares represented hereby are subject to the laws of the State of Delawar |
|
| February 27, 2025 |
Exhibit 10.47 RETENTION BONUS AGREEMENT This Retention Bonus Agreement (this “Agreement”) is made as of April 26, 2024 (the “Effective Date”), between Teladoc Health, Inc. (together with any of its successors or assigns, the “Company”), and Kelly Bliss (the “Employee”). The Company and the Employee are sometimes hereinafter referred to individually as a “Party” and together as “Parties.” WHEREAS, |
|
| February 27, 2025 |
As filed with the Securities and Exchange Commission on February 27, 2025 As filed with the Securities and Exchange Commission on February 27, 2025 Registration No. |
|
| February 27, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) February 26, 2025 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) |
|
| February 26, 2025 |
Teladoc Health Reports Full Year and Fourth Quarter 2024 Results Exhibit 99.1 Teladoc Health Reports Full Year and Fourth Quarter 2024 Results PURCHASE, NY, February 26, 2025— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 (“Full Year 2024”) and three months ended December 31, 2024 (“Fourth Quarter 2024”). Unless otherwise noted, percentage and other c |
|
| October 31, 2024 |
Exhibit 10.1 September 27, 2024 Michael Waters Via e-mail Dear Michael: This letter agreement, (together with the attachments, the “Agreement”), reflects our mutual understanding with respect to your future services and expected separation from Teladoc Health, Inc., a Delaware corporation (the “Company” or “we”) and sets forth the payments and benefits that you will be eligible to receive under th |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3747 |
|
| October 30, 2024 |
Teladoc Health Reports Third Quarter 2024 Results Exhibit 99.1 Teladoc Health Reports Third Quarter 2024 Results PURCHASE, NY, October 30, 2024— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended September 30, 2024 (“Third Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended September 30, 2023 (“Third |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) October 30, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) September 27, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commis |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 9, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) |
|
| September 5, 2024 |
SC 13G 1 p24-2746sc13g.htm TELADOC HEALTH, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) September 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| September 5, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-2746exhibit99.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing a |
|
| August 1, 2024 |
Exhibit 10.4 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TEL |
|
| August 1, 2024 |
Exhibit 10.3 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The C |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) July 31, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04- |
|
| July 31, 2024 |
Teladoc Health Reports Second Quarter 2024 Results Exhibit 99.1 Teladoc Health Reports Second Quarter 2024 Results PURCHASE, NY, July 31, 2024— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended June 30, 2024 (“Second Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended June 30, 2023 (“Second Quarter 20 |
|
| July 8, 2024 |
TDOC / Teladoc Health, Inc. / BlackRock Inc. Passive Investment us87918a1051070824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) Teladoc Health Inc - (Name of Issuer) Common Stock - (Title of Class of Securities) 87918A105 - (CUSIP Number) June 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04- |
|
| June 18, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Teladoc Health, Inc. |
|
| June 18, 2024 |
As filed with the Securities and Exchange Commission on June 18, 2024 As filed with the Securities and Exchange Commission on June 18, 2024 Registration No. |
|
| June 10, 2024 |
, by and between Teladoc Health, Inc. and Charles Divita Exhibit 10.2 EXECUTION VERSION EMPLOYMENT AGREEMENT This Employment Agreement (“Agreement”) is made effective as of June 10, 2024 (“Effective Date”), by and between Teladoc Health, Inc. (the “Company”) and Mr. Charles Divita (“Executive”). WHEREAS, pursuant to the offer letter by and between Executive and the Company, dated as of June 5, 2024 (the “Offer Letter”), Executive has agreed to serve as |
|
| June 10, 2024 |
Exhibit 99.1 Teladoc Health Names Chuck Divita as CEO Experienced Healthcare Leader to Head Global Virtual Care Company PURCHASE, NY, June 10, 2024 - Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced that its Board of Directors has appointed Charles “Chuck” Divita, III, as Chief Executive Officer, effective immediately. Concurrent with his role as C |
|
| June 10, 2024 |
Amendment No. 2 to Executive Severance Agreement, dated June Exhibit 10.3 AMENDMENT NO. 2 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 2 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Ms. Mala Murthy, an individual resident in the State of New York (“Executive”), is made as of June 6, 2024. Recitals A.Teladoc and Executive are parties to that certain E |
|
| June 10, 2024 |
, 2024, by and between Teladoc Health, Inc. and Charles D Exhibit 10.1 EXECUTION VERSION Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. June 5, 2024 Charles Divita via e-mail Dear Chuck, We are pleased to confirm our offer of employment to you with Teladoc Health, Inc. (“Telad |
|
| June 10, 2024 |
First Amendment to Teladoc Health, Inc. 2023 Employment Inducement Award Plan. Exhibit 10.4 FIRST AMENDMENT TO TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN The 2023 Employment Inducement Incentive Award Plan (the “Plan”) of Teladoc Health, Inc., a Delaware corporation (the “Company”), is hereby amended, effective as of June 10, 2024 (the “Effective Date”), as follows: 1.Amendment to Section 11.27 of the Plan. Section 11.27 of the Plan is hereby delete |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) June 5, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commission F |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 2 Manhattanville Road, Suite 203 Purchase, New York 10577 (Address of Princ |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04-3 |
|
| April 26, 2024 |
April 26, 2024, by and between Teladoc Health, Inc. and Adam Vandervoort. Exhibit 10.4 AMENDMENT NO. 2 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 2 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Mr. Adam Vandervoort, an individual resident in the State of Connecticut (“Executive”), is made as of April 26, 2024. Recitals A. Teladoc and Executive are parties to tha |
|
| April 26, 2024 |
Letter Agreement, dated as of April 1, 2024, by and between Teladoc Health, Inc. and Mala Murthy. Exhibit 10.1 TELADOC HEALTH, INC. April 1, 2024 Mala Murthy via e-mail Re: Interim CEO Dear Mala: We are pleased that you have agreed to serve as the Interim Chief Executive Officer (“Interim CEO”) of Teladoc Health, Inc. (the “Company”) effective April 5, 2024. The purpose of this letter agreement (the “Letter Agreement”) is to document your duties and the compensation that you will receive for y |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TE |
|
| April 26, 2024 |
, 2024, by and between Teladoc Health, Inc. and Exhibit 10.3 RETENTION BONUS AGREEMENT This Retention Bonus Agreement (this “Agreement”) is made as of April 26, 2024 (the “Effective Date”), between Teladoc Health, Inc. (together with any of its successors or assigns, the “Company”), and Adam Vandervoort (the “Employee”). The Company and the Employee are sometimes hereinafter referred to individually as a “Party” and together as “Parties.” WHERE |
|
| April 26, 2024 |
Exhibit 10.2 TELADOC HEALTH, INC. April 11, 2024 Jason Gorevic Via e-mail Re: Release and Separation Agreement Dear Jason: Your last day of employment with Teladoc Health, Inc. (the “Company”) was April 5, 2024 (“Separation Date”). In order to receive the separation benefits provided in Section 5(b)(i) of the Amended and Restated Executive Employment Agreement between you and the Company, dated as |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) April 25, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04 |
|
| April 25, 2024 |
Teladoc Health Reports First Quarter 2024 Results Exhibit 99.1 Teladoc Health Reports First Quarter 2024 Results PURCHASE, NY, April 25, 2024— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the three months ended March 31, 2024 (“First Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the three months ended March 31, 2023 (“First Quarter 20 |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 8, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04- |
|
| April 9, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 5, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-37477 (Commission File Number) 04- |
|
| April 5, 2024 |
Teladoc Health Board of Directors Announces Leadership Transition Exhibit 99.1 Teladoc Health Board of Directors Announces Leadership Transition •Jason Gorevic to depart the company, effective immediately •CFO Mala Murthy appointed acting chief executive •Teladoc Health reaffirms guidance PURCHASE, NY, April 5, 2024 (GLOBE NEWSWIRE) - Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today announced that Jason Gorevic is departin |
|
| February 23, 2024 |
Teladoc Health, Inc. Incentive-Based Compensation Recovery Policy Exhibit 97.1 September 21, 2023 Teladoc Health, Inc. Incentive-Based Compensation Recovery Policy The Board of Directors (the “Board”) of Teladoc Health, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation ph |
|
| February 23, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 8i or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEA |
|
| February 23, 2024 |
Exhibit 10.42 AMENDMENT NO. 1 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 1 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Mr. Andrew Turitz, an individual resident in the State of Illinois (“Executive”), is made as of October 29, 2019. Recitals A.Teladoc and Executive are parties to that ce |
|
| February 23, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Teladoc Health, Inc. Name Domestic Jurisdiction Advance Medical, Inc. Massachusetts AM Healthcare Management Consulting Sdn. Bhd. Malaysia Association pour le Déploiement de Parcours de Santé Territoriaux et Phygitaux France Best Doctors Holdings, Inc. Delaware Best Doctors, Inc. Delaware BetterHelp, Inc. Delaware Centro Médico Virtual Teladoc Health S.P.A. Chile Consu |
|
| February 23, 2024 |
Seventh Amended and Restated Bylaws of Teladoc Health, Inc. Exhibit 3.2 SEVENTH AMENDED AND RESTATED BYLAWS OF TELADOC HEALTH, INC. (a Delaware corporation) SEVENTH AMENDED AND RESTATED BYLAWS OF TELADOC HEALTH, INC. ARTICLE I CORPORATE OFFICES Section 1.1 REGISTERED OFFICE. The registered office of Teladoc Health, Inc. (the “Corporation”) shall be fixed in the Corporation’s certificate of incorporation, as the same may be amended from time to time (the “c |
|
| February 23, 2024 |
Exhibit 10.39 EXECUTIVE SEVERANCE AGREEMENT This Executive Severance Agreement (''Agreement”) is made effective as of July 15, 2015 ("Effective Date"), by and between Teladoc, Inc. (the "Company") and Daniel Trencher ("Executive"). WHEREAS, Executive is a key employee of the Company and the Company and Executive desire to set forth herein the terms and conditions of Executive's compensation in the |
|
| February 23, 2024 |
Exhibit 10.37 [Teladoc Health, Inc. Letterhead] December 1, 2023 Claus Jensen [] Re: Separation and Release of Claims Agreement Dear Claus: As we have discussed, your employment with Teladoc Health, Inc. (the “Company”) as Chief Innovation Officer will terminate effective as of December 1, 2023 (“Termination Date”). On your Termination Date, you are to stop all efforts on behalf of the Company. In |
|
| February 23, 2024 |
Teladoc Health, Inc. Non-Employee Director Compensation Program (as amended). Exhibit 10.29 Effective January 1, 2024 TELADOC HEALTH, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Teladoc Health, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be pa |
|
| February 23, 2024 |
Exhibit 10.41 EXECUTIVE SEVERANCE AGREEMENT This Executive Severance Agreement ("Agreement") is made effective as of July 15, 2015 ("Effective Date"), by and between Teladoc, Inc. (the "Company") and Andrew Turitz ("Executive"). WHEREAS, Executive is a key employee of the Company and the Company and Executive desire to set forth herein the terms and conditions of Executive's compensation in the ev |
|
| February 20, 2024 |
Teladoc Health Reports Fourth Quarter and Full Year 2023 Results Exhibit 99.1 Teladoc Health Reports Fourth Quarter and Full Year 2023 Results •Fourth quarter 2023 revenue increase of 4% and full year 2023 revenue increase of 8% to $2,602.4 million •Fourth quarter 2023 net loss of $28.9 million, or $0.17 per share, and full year 2023 net loss of $220.4 million, or $1.34 per share •Fourth quarter 2023 adjusted EBITDA increase of 22% to $114.4 million and full ye |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) February 20, 2024 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commiss |
|
| February 13, 2024 |
TDOC / Teladoc Health, Inc. / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 13, 2024 |
TDOC / Teladoc Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02047-teladochealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Teladoc Health Inc Title of Class of Securities: Common Stock CUSIP Number: 87918A105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designat |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 29, 2024 |
TDOC / Teladoc Health, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm244117d24sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Teladoc Health, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) November 8, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commissi |
|
| October 27, 2023 |
Exhibit 10.4 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The C |
|
| October 27, 2023 |
Exhibit 10.3 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN RESTRICTED STOCK GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company has |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3747 |
|
| October 27, 2023 |
Exhibit 10.5 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc |
|
| October 27, 2023 |
Exhibit 10.2 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Employment Inducement Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company hereby gran |
|
| October 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) October 24, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commissi |
|
| October 24, 2023 |
Teladoc Health Reports Third Quarter 2023 Results Exhibit 99.1 Teladoc Health Reports Third Quarter 2023 Results •Third quarter 2023 revenue grows 8% year-over-year to $660.2 million •Third quarter 2023 operating cash flow of $105.6 million; free cash flow of $68.0 million •Third quarter 2023 net loss of $57.1 million, or $0.35 per share •Third quarter 2023 adjusted EBITDA of $88.8 million, up 73% year-over-year PURCHASE, NY, October 24, 2023— Te |
|
| September 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) September 20, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commis |
|
| September 20, 2023 |
Teladoc Health Appoints Leading Healthcare and Hospitals Executive Eric Evans to Board of Directors Exhibit 99.1 Teladoc Health Appoints Leading Healthcare and Hospitals Executive Eric Evans to Board of Directors Purchase, NY, September 20, 2023 – Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today appointed Eric Evans to the company’s board of directors. Mr. Evans, currently chief executive officer and director of Brentwood, TN-based Surgery Partners, Inc. (N |
|
| July 28, 2023 |
Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan. Exhibit 99.1 TELADOC HEALTH, INC. 2023 EMPLOYMENT INDUCEMENT INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II |
|
| July 28, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Teladoc Health, Inc. |
|
| July 28, 2023 |
Form of Restricted Stock Unit Agreement under the Teladoc Health, Inc. 2023 Incentive Award Plan. Exhibit 10.4 TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company hereby grants to the participant list |
|
| July 28, 2023 |
Form of Stock Option Agreement under the Teladoc Health, Inc. 2023 Incentive Award Plan. Exhibit 10.2 TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company hereby grants to the participant listed below (“Partici |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TEL |
|
| July 28, 2023 |
Exhibit 10.9 AMENDMENT NO. 2 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 2 to Executive Severance Agreement (this “Second Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Mr. Andrew Turitz, an individual resident in the State of Illinois (“Executive”), is made as of June 9th, 2023. Recitals A. Teladoc and Executive are parties to th |
|
| July 28, 2023 |
Exhibit 10.8 AMENDMENT NO. 1 TO EXECUTIVE SEVERANCE AGREEMENT This Amendment No. 1 to Executive Severance Agreement (this “Amendment”), by and between Teladoc Health, Inc., a Delaware corporation (“Teladoc” or the “Company”), and Mr. Daniel Trencher, an individual resident in the State of New York (“Executive”), is made as of June 9th, 2023. Recitals A. Teladoc and Executive are parties to that ce |
|
| July 28, 2023 |
As filed with the Securities and Exchange Commission on July 28, 2023 As filed with the Securities and Exchange Commission on July 28, 2023 Registration No. |
|
| July 28, 2023 |
Form of Restricted Stock Agreement under the Teladoc Health, Inc. 2023 Incentive Award Plan. Exhibit 10.3 TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN RESTRICTED STOCK GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company has granted to the participant listed below (“P |
|
| July 28, 2023 |
Exhibit 10.5 TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2023 Incentive Award Plan (as amended from time to time, the “Plan”) of Teladoc Health, Inc. (the “Company”). The Company hereby grants |
|
| July 25, 2023 |
Teladoc Health Reports Second Quarter 2023 Results Exhibit 99.1 Teladoc Health Reports Second Quarter 2023 Results •Second quarter 2023 revenue grows 10% year-over-year to $652.4 million •Second quarter 2023 operating cash flow of $101.2 million; free cash flow of $64.6 million •Second quarter 2023 net loss of $65.2 million, or $0.40 per share •Second quarter 2023 adjusted EBITDA of $72.2 million PURCHASE, NY, July 25, 2023— Teladoc Health, Inc. ( |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported) July 25, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 001-37477 (Commission |
|
| July 10, 2023 |
TDOC / Teladoc Health Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Teladoc Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87918A105 Date of Event Which Requires Filing of this Statement: June 30, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rul |
|
| May 30, 2023 |
Teladoc Health, Inc. Level 14 Severance Plan. Exhibit 10.3 TELADOC HEALTH, INC. LEVEL 14 SEVERANCE PLAN The Company has adopted this Level 14 Severance Plan (the “Plan”) for the benefit of certain management and highly compensated employees of the Company and its subsidiaries, on the terms and conditions hereinafter stated. All capitalized terms used herein are defined in Section 1 hereof. The Plan, as set forth herein, is intended to help re |
|
| May 30, 2023 |
Teladoc Health, Inc. 2023 Incentive Award Plan. Exhibit 10.1 TELADOC HEALTH, INC. 2023 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBILIT |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 30, 2023 |
Second Amendment to Teladoc Health, Inc. Amended and Restated Employee Stock Purchase Plan. Exhibit 10.2 SECOND AMENDMENT TO TELADOC HEALTH, INC. AMENDED AND RESTATED EMPLOYEE STOCK PURCHASE PLAN The 2015 Employee Stock Purchase Plan, amended and restated as of May 9, 2021, (the “Plan”) of Teladoc Health, Inc., a Delaware corporation (the “Company”), is hereby further amended, effective as of May 25, 2023 (the “Effective Date”), as follows: 1. Amendment to Section 3.1 of the Plan. Sectio |
|
| May 30, 2023 |
EX-FILING FEES 4 tm2317113d2ex-filingfees.htm EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Teladoc Health, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 30, 2023 ( May 25, 2023) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (C |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 2 Manhattanville Road, Suite 203 Purchase, New York 10577 (Address of Princ |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents DeferredTaxAssetsDeferredIncome UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 26, 2023 |
Teladoc Health Reports First Quarter 2023 Results Exhibit 99.1 Teladoc Health Reports First Quarter 2023 Results ● First quarter 2023 revenue grows 11% year-over-year to $629.2 million ● First quarter 2023 net loss of $69.2 million, or $0.42 per share ● First quarter adjusted EBITDA totaled $52.8 million PURCHASE, NY, April 26, 2023— Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial result |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 26, 2023 Teladoc Health, Inc. |
|
| April 11, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 1, 2023 |
Exhibit 10.25 HOME OFFICE OPERATING AGREEMENT This HOME OFFICE OPERATING AGREEMENT (“Agreement”) is made and entered into effective as of January 1, 2023 (“Effective Date”) by and between: Teladoc Health, Inc., a company organized and existing under the laws of Delaware, with its registered office located at 251 Little Falls Drive, Wilmington, Delaware 19808 (“Teladoc”) and Claus Jensen, an indivi |
|
| March 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 8i or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALT |
|
| March 1, 2023 |
Offer Letter, dated March 19, 2021, by and between Teladoc Health, Inc. and Claus Jensen. Exhibit 10.24 2 Manhattanville Road, Suite 203 ⧫ Purchase ⧫ New York 10577 ⧫ (203) 742-1719 March 19, 2021 Claus Jensen ADDRESS: [ ] Dear Claus, We are pleased to confirm our offer of employment to you with Teladoc Health, Inc. for the position of Chief Innovation Officer. Your start date will be April 26, 2021. You will report to Jason Gorevic, CEO. Your work location will be from our Purchase Of |
|
| March 1, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Teladoc Health, Inc. |
|
| March 1, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Teladoc Health, Inc. Name Domestic Jurisdiction AcuteCare Telemedicine, LLC Georgia Advance Medical, Inc. Massachusetts AM Healthcare Management Consulting Sdn. Bhd. Malaysia Association pour le Déploiement de Parcours de Santé Territoriaux et Phygitaux France Best Doctors Holdings, Inc. Delaware Best Doctors International Insurance S.a.r.l. Luxembourg Best Doctors, In |
|
| March 1, 2023 |
Exhibit 4.10 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Teladoc Health, Inc. (“Teladoc Health,” “we,” “us” or “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share (the “common stock”). As of March 1, 2023, we had 300,000 |
|
| March 1, 2023 |
Exhibit 4.9 EXECUTION VERSION SECOND SUPPLEMENTAL INDENTURE This SECOND SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of January 1, 2023, is entered into among Livongo Health, Inc., a Delaware corporation (the “Company”), Teladoc Health, Inc., a Delaware corporation (“Teladoc”), and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Ass |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on March 1, 2023 As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| February 22, 2023 |
Teladoc Health Reports Fourth Quarter and Full Year 2022 Results Exhibit 99.1 Teladoc Health Reports Fourth Quarter and Full Year 2022 Results ● Fourth quarter revenue grows 15% year-over-year to $637.7 million and full year revenue grows 18% year-over-year to $2,406.8 million ● 2022 full year cash flow from operating activities and free cash flow was $189.3 million and $16.5 million, respectively; Cash position of $918.2 million as of December 31, 2022 ● Fourt |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 22, 2023 Teladoc Health, Inc. |
|
| February 10, 2023 |
TDOC / Teladoc, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 10, 2023 |
TDOC / Teladoc, Inc. / Nikko Asset Management Americas, Inc. - SC 13G/A Passive Investment SC 13G/A 1 brhc10047843sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Ch |
|
| February 9, 2023 |
TDOC / Teladoc, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02017-teladochealthinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Teladoc Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87918A105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designa |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 18, 2023 |
Subject: Difficult Steps Towards Integration & Balanced Growth Exhibit 99.1 Subject: Difficult Steps Towards Integration & Balanced Growth Dear Colleagues, Today we are taking the difficult but necessary step of letting go approximately 300 colleagues or 6% of Teladoc Health’s non-clinician workforce. This is not a decision I take lightly, and we will do all we can to help our colleagues through this moment. One of the first questions you may have is why is t |
|
| January 18, 2023 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 18, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 9, 2023 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fil |
|
| November 2, 2022 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is made and entered into as of June 15, 2022 (the ?Effective Date?), by and between Teladoc Health, Inc. (the ?Company?) and Michael Waters, an individual, residing at [ ] (the ?Executive?). ? 1.Employment. During the period of Executive?s employment with the Company, the Company shall employ Executiv |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents DeferredTaxAssetsDeferredIncome ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 28, 2022 |
Teladoc Health Names Laizer Kornwasser as President, Enterprise Growth & Global Markets Exhibit 99.1 Teladoc Health Names Laizer Kornwasser as President, Enterprise Growth & Global Markets PURCHASE, NY, October 24, 2022 - Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, has named Laizer Kornwasser as president, enterprise growth and global markets. In this role, Kornwasser is charged with further unlocking the revenue and profit growth potential of the com |
|
| October 28, 2022 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is made and entered into as of the last date written below (the “Effective Date”), by and between Teladoc Health, Inc. (the “Company”) and Laizer Kornwasser, an individual, residing at [ ] (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Executive wishes to be employed b |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 28, 2022 ( October 24, 2022) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorpora |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 26, 2022 Teladoc Health, Inc. |
|
| October 26, 2022 |
Teladoc Health Reports Third-Quarter 2022 Results Exhibit 99.1 Teladoc Health Reports Third-Quarter 2022 Results ● Third quarter revenue grows 17% year-over-year to $611.4 million ● Net loss totaled $73.5 million, or $0.45 per share ● Adjusted EBITDA totaled $51.2 million ● Cash flow from operating activities was $63.0 million for the quarter and $123.7 million year-to-date PURCHASE, NY, October 26, 2022— Teladoc Health, Inc. (NYSE: TDOC), the gl |
|
| October 3, 2022 |
October 3, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Division of Corporation Finance Disclosure Review Program Re: Teladoc Health, Inc. |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents DeferredTaxAssetsDeferredIncome ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 3, 2022 |
Teladoc Health, Inc. Non-Employee Director Compensation Program (as amended). Exhibit 10.1 ? Effective January 1, 2022 ? TELADOC HEALTH, INC. ? NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM ? Non-employee members of the board of directors (the ?Board?) of Teladoc Health, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program shal |
|
| July 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 ? ? FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): July 27, 2022 ? ? ? Teladoc Health, Inc. |
|
| July 27, 2022 |
Teladoc Health Reports Second-Quarter 2022 Results EX-99.1 2 tdoc-20220727xex99d1.htm EX-99.1 Exhibit 99.1 Teladoc Health Reports Second-Quarter 2022 Results ● Second quarter revenue grows 18% year-over-year to $592.4 million. ● Net loss per share of $19.22, primarily driven by non-cash goodwill impairment charge of $3.0 billion, or $18.78 per share. ● Primary360 adds multiple new clients, and new capabilities, as early momentum continues PURCHASE |
|
| July 25, 2022 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?) is made and entered into as of June 15, 2022 (the ?Effective Date?), by and between Teladoc Health, Inc. (the ?Company?) and Michael Waters, an individual, residing at Michael Waters, 26131 Red Corral Road, Laguna Hills, CA 92653 (the ?Executive?). 1. Employment. During the period of Executive?s emplo |
|
| July 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) July 25, 2022 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission File |
|
| July 25, 2022 |
Teladoc Health Names Mike Waters as Chief Operating Officer Exhibit 99.1 Teladoc Health Names Mike Waters as Chief Operating Officer PURCHASE, NY, July 25, 2022 - Teladoc Health (NYSE: TDOC), the global leader in whole-person virtual care, has named Mike Waters as chief operating officer. As COO, Waters will work closely with Jason Gorevic, CEO of Teladoc Health, on the organization?s overall operations and execution and will take primary responsibility fo |
|
| June 2, 2022 |
Seventh Amended and Restated Certificate of Incorporation of Teladoc Health, Inc. Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TELADOC HEALTH, INC. Teladoc Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), certifies that: 1. The name of the Corporation is Teladoc Health, Inc. The Corporation?s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaw |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 2, 2022 ( May 26, 2022) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (C |
|
| June 2, 2022 |
Sixth Amended and Restated Bylaws of Teladoc Health, Inc. Exhibit 3.2 SIXTH AMENDED AND RESTATED BYLAWS OF TELADOC HEALTH, INC. (a Delaware corporation) TABLE OF CONTENTS Page Article I CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 Article II MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 5 2.5 ADVANCE NOTICE PROCEDURES FOR |
|
| May 2, 2022 |
? Exhibit 10.1 ? TELADOC HEALTH, INC. 2015 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2015 Incentive Award Plan (as amended from time to time, the ?Plan?) of Teladoc Health, Inc. (f/k/a Teladoc, Inc.) (the ?Company?). |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 27, 2022 Teladoc Health, Inc. |
|
| April 27, 2022 |
Teladoc Health Reports First Quarter 2022 Results ? Exhibit 99.1 ? Teladoc Health Reports First Quarter 2022 Results ? ? First quarter revenue grows 25% year-over-year to $565.4 million ? ? Net loss per share of $41.58, primarily driven by non-cash goodwill impairment charge of $6.6 billion or $41.11 per share ? ? Full year guidance ranges for 2022 revenue, net loss per share and adjusted EBITDA revised to $2.4 - $2.5 billion, ($43.50) per share |
|
| April 12, 2022 |
DEF 14A 1 tm2128566-2def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 31, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ???) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| February 28, 2022 |
Subsidiaries of the Registrant. EX-21.1 2 tdoc-20211231xex21d1.htm EX-21.1 Exhibit 21.1 Subsidiaries of Teladoc Health, Inc. Name Domestic Jurisdiction AcuteCare Telemedicine, LLC Georgia Advance Medical Health Care Management Services Chile S.A. Chile Advance Medical, Inc. Massachusetts AM Healthcare Management Consulting Sdn. Bhd. Malaysia Best Doctors Holdings, Inc. Delaware Best Doctors International Insurance S.a.r.l. Luxem |
|
| February 28, 2022 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 22, 2022 |
Teladoc Health Reports Fourth Quarter and Full Year 2021 Results Exhibit 99.1 ? Teladoc Health Reports Fourth Quarter and Full Year 2021 Results ? ? Fourth quarter revenue grows 45% year-over-year to $554.2 million and total visits increase 41% to 4.4 million ? ? Full year revenue grows 86% year-over-year to $2,032.7 million and total visits increase 38% to 15.4 million ? ? Full year cash flows from operations grew to $194.0 million ? ? Full year 2022 Revenue g |
|
| February 22, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 ? ? FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): February 22, 2022 ? ? ? Teladoc Health, Inc. |
|
| February 14, 2022 |
TDOC / Teladoc, Inc. / Nikko Asset Management Americas, Inc. - SC13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 10, 2022 |
TDOC / Teladoc, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Teladoc Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87918A105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? |
|
| February 9, 2022 |
TDOC / Teladoc, Inc. / ARK Investment Management LLC - SC 13G/A Passive Investment SC 13G/A 1 tm225659d45sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Teladoc Health, Inc. (Name of Issuer) Common stock (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 4, 2022 |
TDOC / Teladoc, Inc. / Sumitomo Mitsui Trust Holdings, Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a)* Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 3, 2022 |
CORRESP 1 filename1.htm February 3, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Division of Corporation Finance Office of Life Sciences Re: Teladoc Health, Inc. Form 10-K for Fiscal Year Ended December 31, 2020 Filed March 1, 2021 File No: 001-37477 Response Dated January 14, 2022 Dear Ms. Houser and Mr. O |
|
| January 14, 2022 |
January 14, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Attention: Division of Corporation Finance Office of Life Sciences Re: Teladoc Health, Inc. |
|
| January 10, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 10, 2022 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 18, 2021 |
Exhibit 99.1 This presentation contains, and our officers may make, ?forward-looking? statements that are based on our management?s beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limitation, information concerning possible or assumed future results of operations, including descriptions of our business plan and strateg |
|
| November 18, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 18, 2021 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission F |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3747 |
|
| November 1, 2021 |
Teladoc Health, Inc. Senior Leader Severance Plan. Exhibit 10.1 ? TELADOC HEALTH, INC. SENIOR LEADER SEVERANCE PLAN The Company has adopted this Severance Plan (the ?Plan?) for the benefit of certain employees of the Company and its subsidiaries, on the terms and conditions hereinafter stated. All capitalized terms used herein are defined in Section 1 hereof. The Plan, as set forth herein, is intended to help retain qualified employees, maintain a |
|
| October 27, 2021 |
Teladoc Health Reports Third-Quarter 2021 Results Exhibit 99.1 ? Teladoc Health Reports Third-Quarter 2021 Results ? ? Third quarter revenue grows 81% year-over-year to $522 million, updating 2021 revenue outlook to $2,015 million to $2,025 million. ? ? Total third quarter visits top 3.9 million ? 37% higher than Q3 2020. ? ? Significant new agreements with CVS Health and Centene to provide Teladoc Health?s Primary360 to deliver greater care acce |
|
| October 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 ? ? FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): October 27, 2021 ? ? ? Teladoc Health, Inc. |
|
| September 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) September 20, 2021 (September 17, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorp |
|
| August 16, 2021 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 16, 2021 (August 13, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporatio |
|
| August 4, 2021 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 4, 2021 (August 3, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) |
|
| August 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 2, 2021 |
Teladoc Health, Inc. 2015 Employee Stock Purchase Plan. Exhibit 10.1 TELADOC HEALTH, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN (as amended and restated effective May 9, 2021) ARTICLE I. PURPOSE The purposes of this Teladoc Health, Inc. 2015 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the ?Plan?) are to assist Eligible Employees of Teladoc Health, Inc., a Delaware corporation (the ?Company?), and its Designated Subsidi |
|
| July 27, 2021 |
Teladoc Health Reports Second-Quarter 2021 Results, Raises Full-Year Revenue Guidance Exhibit 99.1 ? Teladoc Health Reports Second-Quarter 2021 Results, Raises Full-Year Revenue Guidance ? ? Second quarter revenue grows 109% year-over-year to $503 million, driving 2021 revenue outlook increase to $2,000 million to $2,025 million. ? ? Total second quarter visits top 3.5 million ? 28% higher than Q2 2020, in the first wave of the pandemic. ? ? Significant new agreement with HCSC to p |
|
| July 27, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 ? ? FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): July 27, 2021 ? ? Teladoc Health, Inc. |
|
| June 17, 2021 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) June 16, 2021 (June 16, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) ( |
|
| May 27, 2021 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 27, 2021 (May 26, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Co |
|
| May 18, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 18, 2021 (May 17, 2021) Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Co |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| May 3, 2021 |
? Exhibit 10.1 ? TELADOC HEALTH, INC. 2015 INCENTIVE AWARD PLAN PERFORMANCE RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Performance Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2015 Incentive Award Plan (as amended from time to time, the ?Plan?) of Teladoc Health, Inc. (f/k/a Teladoc, Inc.) (the ?Company?). |
|
| May 3, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TE |
|
| April 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 ? ? FORM 8-K ? ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of report (Date of earliest event reported): April 28, 2021 ? ? Teladoc Health, Inc. |
|
| April 28, 2021 |
Teladoc Health Reports First-Quarter 2021 Results Exhibit 99.1 ? Teladoc Health Reports First-Quarter 2021 Results ? PURCHASE, NY, April 28, 2021??Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the first quarter ended March 31, 2021. ? Highlights ? ? Raises full-year guidance as first quarter revenue grows 151% year-over-year to $453.7 million, with total visits increasing 5 |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) Kinnevik AB (publ) Skeppsbron 18 P.O. Box 2094 SE-103 13 Stockholm, Sweden +46 8 562 000 00 (Name, Address and Telephone |
|
| April 7, 2021 |
DEF 14A 1 tm212496-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 16, 2021 |
SC 13D/A 1 d123641dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Teladoc Health, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87918A105 (CUSIP Number) Christopher McCain General Catalyst Partners 20 University Road, 4th Floor, Cambridge, M |
|
| March 16, 2021 |
EX-99.1 EXHIBIT 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Teladoc Health, Inc. EXECUTED this 16th day of March, 2021. GENERAL CATALYST GROUP VI, L.P. By: GEN |
|
| March 1, 2021 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of Teladoc Health, Inc. Name Domestic Jurisdiction AcuteCare Telemedicine, LLC Georgia Advance Holdco Limited England and Wales Advance Medical Health Care Management Services Chile S.A. Chile Advance Medical, Inc. Massachusetts AI + AI, LLC Delaware AM Healthcare Management Consulting Sdn. Bhd. Malaysia Best Doctors Australasia Pty Limited Australia Best Doctors Holdings |
|
| March 1, 2021 |
Exhibit 10.2 ? INDEMNIFICATION AGREEMENT by and between ? TELADOC HEALTH, INC. ? and as Indemnitee ? ? ? ? ? ? ? ? ? ? ? Dated as of ? ? ? ? ? ? ? ? ? ? TABLE OF CONTENTS ? ? Page ARTICLE 1 DEFINITIONS 2 ? ? ARTICLE 2 INDEMNITY IN THIRD-PARTY PROCEEDINGS 6 ? ? ARTICLE 3 INDEMNITY IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY 7 ? ? ARTICLE 4 INDEMNIFICATION FOR EXPENSES OF A PARTY WHO IS WHOLLY |
|
| March 1, 2021 |
Exhibit 10.16 ? TELADOC HEALTH, INC. LIVONGO ACQUISITION INCENTIVE AWARD PLAN ? RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the Teladoc Health, Inc. Livongo Acquisition Incentive Award Plan (as amended from time to time, the ?Plan?) of Teladoc Health, Inc. (the ?Comp |
|
| March 1, 2021 |
Exhibit 10.14 ? TELADOC HEALTH, INC. LIVONGO ACQUISITION INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the ?Grant Notice?) have the meanings given to them in the Teladoc Health, Inc. Livongo Acquisition Incentive Award Plan (as amended from time to time, the ?Plan?) of Teladoc Health, Inc. (the ?Company?). The Company h |
|
| March 1, 2021 |
Exhibit 4.11 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Teladoc Health, Inc. (?Teladoc Health,? ?we,? ?us? or ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share (the ?common stock?). As of March 1, 2021, we had 300,000 |
|
| March 1, 2021 |
As filed with the Securities and Exchange Commission on March 1, 2021 Registration No. |
|
| March 1, 2021 |
Exhibit 10.15 ? TELADOC HEALTH, INC. LIVONGO ACQUISITION INCENTIVE AWARD PLAN ? RESTRICTED STOCK GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Grant Notice (the ?Grant Notice?) have the meanings given to them in the Teladoc Health, Inc. Livongo Acquisition Incentive Award Plan (as amended from time to time, the ?Plan?) of Teladoc Health, Inc. (the ?Company?). The |
|
| March 1, 2021 |
Teladoc Health, Inc. Non-Employee Director Compensation Program (as amended). Exhibit 10.18 ? Effective January 1, 2021 ? TELADOC HEALTH, INC. ? NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM ? Non-employee members of the board of directors (the ?Board?) of Teladoc Health, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program sha |
|
| March 1, 2021 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 24, 2021 |
EX-99.1 2 tdoc-20210224xex99d1.htm EX-99.1 Exhibit 99.1 Teladoc Health Reports Fourth-Quarter and Full-Year 2020 Results Q4 revenue grows 145% year-over-year to $383.3 million and total visits increase 139% to 3.0 million Full year revenue grows 98% year-over-year to $1,094.0 million and total visits increase 156% to 10.6 million Issues 2021 first-quarter and full-year guidance PURCHASE, NY, Febru |
|
| February 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 24, 2021 Teladoc Health, Inc. |
|
| February 19, 2021 |
Fifth Amended and Restated Bylaws of Teladoc Health, Inc. Exhibit 3.1 FIFTH AMENDED AND RESTATED BYLAWS OF TELADOC HEALTH, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES |
|
| February 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) February 19, 2021 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission F |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Teladoc Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87918A105 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| January 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 28, 2021 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 11, 2021 |
Teladoc Health, Inc. slide presentation, dated January 11, 2021. EX-99.1 2 tm212222d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 |
|
| January 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 11, 2021 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 21, 2020 |
EX-99.1 2 ea132030ex99-1teladoc.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT THIS JOINT FILING AGREEMENT (this “Agreement”) is made and entered into as of this 21st day of December 2020, by and among Kinnevik AB (publ) and Invik S.A. In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the parties to this Agreement hereby |
|
| December 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) Kinnevik AB (publ) Skeppsbron 18 P.O. Box 2094 SE-103 13 Stockholm, Sweden +46 8 562 000 00 (Name, Address and Telephone |
|
| November 20, 2020 |
SC 13D/A 1 d15920dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Teladoc Health, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87918A105 (CUSIP Number) Christopher McCain General Catalyst Partners 20 University Road, 4th Floor, Cambridge, MA |
|
| November 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 30, 2020 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporati |
|
| November 20, 2020 |
EX-99.1 EXHIBIT 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Teladoc Health, Inc. EXECUTED this 19th day of November, 2020. GENERAL CATALYST GROUP VI, L.P. By: |
|
| November 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) November 10, 2020 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission F |
|
| November 10, 2020 |
EX-99.1 2 d947692dex991.htm EX-99.1 EXHIBIT 99.1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Teladoc Health, Inc. EXECUTED this 10th day of November, 2020. GENERAL |
|
| November 10, 2020 |
TDOC / Teladoc, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Teladoc Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 87918A105 Date of Event Which Requires Filing of this Statement: October 30, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ |
|
| November 10, 2020 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Teladoc Health, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87918A105 (CUSIP Number) Christopher McCain General Catalyst Partners 20 University Road, 4th Floor, Cambridge, MA 02138 (617) 234-7000 (Name, Addre |
|
| November 9, 2020 |
TDOC / Teladoc, Inc. / Kinnevik AB (publ) - FORM SC13D Activist Investment SC 13D 1 dp140530sc13d.htm FORM SC13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Teladoc Health, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 87918A105 (CUSIP Number) Kinnevik AB (publ) Skeppsbron 18 P.O. Box 2094 SE-103 13 Stockholm, Sweden +46 8 562 000 00 With cop |
|
| November 6, 2020 |
As filed with the Securities and Exchange Commission on November 5, 2020 Registration No. |
|
| November 6, 2020 |
Teladoc Health, Inc. Livongo Acquisition Incentive Award Plan. EX-99.1 5 tm2034837d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 TELADOC HEALTH, INC. LIVONGO ACQUISITION INCENTIVE AWARD PLAN (effective October 30, 2020) Article I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company in connection with the Company’s acquisition of Livongo by prov |
|
| November 6, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-3747 |
|
| November 6, 2020 |
As filed with the Securities and Exchange Commission on November 5, 2020 Registration No. |
|
| November 5, 2020 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on November 5, 2020 Registration No. |
|
| October 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 29, 2020 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 30, 2020 |
Exhibit 4.1 FIRST SUPPLEMENTAL INDENTURE This FIRST SUPPLEMENTAL INDENTURE, dated as of October 30, 2020 (the “First Supplemental Indenture”), is entered into among Livongo Health, Inc., a Delaware corporation (the “Company”), Teladoc Health, Inc., a Delaware corporation (“Teladoc”) and U.S. Bank National Association (the “Trustee”). WHEREAS, the Company has heretofore executed and delivered to th |
|
| October 30, 2020 |
EX-3.1 2 tm2026658d62ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TELADOC HEALTH, INC. It is hereby certified that: FIRST. The name of this corporation (hereinafter called the “Corporation”) is TELADOC HEALTH, INC. SECOND. The Sixth Amended and Restated Certificate of Incorporation of the Corporation is hereby amended |
|
| October 30, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 29, 2020 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 30, 2020 |
EX-99.1 5 tm2026658d62ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Teladoc Health Completes Merger with Livongo Combination Creates the Global Leader in Whole-Person Virtual Care October 30, 2020, Purchase, NY – Teladoc Health (NYSE: TDOC), the global leader in whole person virtual care, today announced that it has completed its merger with Livongo. The milestone marks completion of the most significant b |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 29, 2020 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 29, 2020 |
Teladoc Health Announces Shareholder Approvals in Merger with Livongo EX-99.1 2 tm2026658d61ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Teladoc Health Announces Shareholder Approvals in Merger with Livongo October 29, 2020, Purchase, NY – Teladoc Health (TDOC), the global leader in whole person virtual care, today announced that its shareholders have overwhelmingly showed their support for the merger with Livongo (LVGO) by voting to approve the Teladoc Health charter amend |
|
| October 29, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 29, 2020 Teladoc Health, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37477 04-3705970 (State or other jurisdiction of incorporation) (Commission Fi |
|
| October 28, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, District of Columbia 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 28, 2020 Teladoc Health, Inc. |
|
| October 28, 2020 |
Exhibit 99.1 Teladoc Health Reports Third-Quarter 2020 Results Year-over-year Q3 revenue grows 109% to $288.8 million and total visits increase 206% to 2.8 million Year-over-year nine months revenue grows 79% to $710.6 million and total visits increase 163% to 7.6 million Issues 2020 fourth-quarter guidance, raises full-year expectations PURCHASE, NY, October 28, 2020 — Teladoc Health, Inc. (NYSE: |
|
| October 27, 2020 |
Filed by Teladoc Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Livongo Health, Inc. Commission File No. 001-38983 Date: October 27, 2020 The following communication was made available by Teladoc Health, Inc. on Twitter on October 27, 2020. Cautionary Note Regarding Forward-Lookin |
|
| October 23, 2020 |
Filed by Teladoc Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Livongo Health, Inc. Commission File No. 001-38983 Date: October 23, 2020 The following communication was made available by Teladoc Health, Inc. on Twitter on October 23, 2020. Cautionary Note Regarding Forward-Lookin |
|
| October 21, 2020 |
Filed by Teladoc Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Livongo Health, Inc. Commission File No. 001-38983 Date: October 21, 2020 The following communication was made available by Teladoc Health, Inc. on Twitter on October 20, 2020. Cautionary Note Regarding Forward-Lookin |
|
| October 16, 2020 |
Filed by Teladoc Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Livongo Health, Inc. Commission File No. 001-38983 Date: October 15, 2020 The following communication were made available by Teladoc Health, Inc. on Twitter on October 13 and 15, 2020. Cautionary Note Regarding Forwar |
|
| October 15, 2020 |
Filed by Teladoc Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Livongo Health, Inc. Commission File No. 001-38983 Date: October 15, 2020 The following communication was made by Teladoc Health, Inc. (“Teladoc Health”), to Teladoc Health’s employees on October 15, 2020. Subject: Se |
|
| October 15, 2020 |
Filed by Teladoc Health, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Livongo Health, Inc. Commission File No. 001-38983 Date: October 15, 2020 Dear Fellow Stockholder: Teladoc Health’s Special Meeting of stockholders on October 29, 2020 is rapidly approaching, and your Board of Directo |
